Therapeutic Classification: antipsychotics, antidepressants
Pharmacologic Classification: serotonin-dopamine activity modulators (SDAM)
BEERS REMS
Absorption: Well absorbed (95%) following oral administration.
Distribution: Displays extravascular distribution.
Protein Binding: >99%.
Half-Life: 91 hr.
(improvement in symptoms)
ROUTE | ONSET | PEAK | DURATION |
---|---|---|---|
PO (schizophrenia) | within 12 wk | 46 wk | unknown |
PO (depression) | within 1 wk | 5 wk | unknown |
Contraindicated in:
Use Cautiously in:
CV: cerebrovascular adverse reactions (↑ in elderly patients with dementia-related psychoses), orthostatic hypotension/syncope
EENT: blurred vision
Endo: hyperglycemia/diabetes
GI: abdominal pain, constipation, diarrhea, dry mouth, dysphagia, excess salivation, flatulence
Hemat: agranulocytosis, leukopenia, neutropenia
Neuro: akathisia, abnormal dreams, cognitive impairment, dizziness, drowsiness, dystonia, extrapyramidal symptoms, headache, NEUROLEPTIC MALIGNANT SYNDROME, restlessness, sedation, SEIZURES, tardive dyskinesia, tremor, urges (eating, gambling, sexual, shopping)
Misc: body temperature dysregulation, HYPERSENSITIVITY REACTIONS (INCLUDING ANAPHYLAXIS)
Drug-drug:
Drug-Natural Products:
Schizophrenia
Renal Impairment
Hepatic Impairment
Major Depressive Disorder
Renal Impairment
Hepatic Impairment
Agitation Associated with Dementia Due to Alzheimers Disease
Renal Impairment
Hepatic Impairment
Lab Test Considerations: